首页 > 最新文献

Surgical Oncology Insight最新文献

英文 中文
Incidence of metastatic tumors to ovary (Krukenberg) versus primary ovarian neoplasms associated with colorectal cancer surgery 与结直肠癌手术相关的卵巢转移性肿瘤(克鲁肯伯格)和原发性卵巢肿瘤的发病率
Pub Date : 2024-07-11 DOI: 10.1016/j.soi.2024.100079

Background

An ovarian mass in the setting of colorectal cancer (CRC) can be concerning due to the uncertainty of it being metastatic disease or primary ovarian neoplasm, leading to different referral and treatment options. Our objective was to determine the incidence of ovarian metastasis compared to primary ovarian pathology in women diagnosed with CRC.

Methods

Women aged 18 years or older, diagnosed with CRC in 2014 were included. 806 records were screened for findings of an ovarian mass until 2023. Pathology was determined via resection, biopsy, or imaging with follow-up.

Results

Forty women (5.0 %) had an ovarian mass; 11 at index surgery and 29 on follow-up. Median age at CRC diagnosis was 62.7 years. The incidence of Krukenberg tumour (KT) was 3.2 % accounting for 65 % of ovarian masses. Approximately 20 % presented with synchronous KTs (n = 5) and 53.8 % had synchronous peritoneal carcinomatosis (n = 14). On follow-up, KTs were found in 72.4 % of the patients (n = 21). The Overall Survival (OS) in the KT group was 7.8 % with median survival of 30.4 months. The median time to developing KTs was 20.8 months with 2-year disease-free survival of 19.2 %. Synchronous KT presentation was the only factor associated with worse OS on univariate and multivariate analysis (HR 7.23, 95 % CI 1.57–33.28, P < 0.05).

Conclusion

The risk of developing KT in women with CRC is 3.2 %, of which most (72.4 %) present with metachronous disease within 2 years of CRC diagnosis. Initial evaluation by a gastrointestinal tumor group is warranted.

Synopsis

In this multicenter study involving 806 women diagnosed with colorectal cancer, most ovarian masses that were detected during or following surgery are colorectal metastases and not primary ovarian pathology.

背景由于不确定是转移性疾病还是原发性卵巢肿瘤,结直肠癌(CRC)患者的卵巢肿块可能令人担忧,从而导致不同的转诊和治疗方案。我们的目的是确定在确诊为 CRC 的女性中,卵巢转移的发生率与原发性卵巢病变的发生率。筛查了 806 份记录,以发现卵巢肿块,直至 2023 年。结果40名女性(5.0%)有卵巢肿块,其中11人在手术时发现,29人在随访时发现。确诊为 CRC 时的中位年龄为 62.7 岁。克鲁肯伯格肿瘤(KT)的发病率为 3.2%,占卵巢肿块的 65%。约20%的患者伴有同步KT(5例),53.8%的患者伴有同步腹膜癌(14例)。在随访中,72.4%的患者(21 人)发现了 KT。KT组的总生存期(OS)为7.8%,中位生存期为30.4个月。出现KT的中位时间为20.8个月,2年无病生存率为19.2%。在单变量和多变量分析中,同步KT是唯一与较差的OS相关的因素(HR 7.23,95 % CI 1.57-33.28,P < 0.05)。在这项涉及 806 名确诊为结直肠癌的女性的多中心研究中,大多数在手术中或手术后发现的卵巢肿块是结直肠转移瘤,而非原发性卵巢病变。
{"title":"Incidence of metastatic tumors to ovary (Krukenberg) versus primary ovarian neoplasms associated with colorectal cancer surgery","authors":"","doi":"10.1016/j.soi.2024.100079","DOIUrl":"10.1016/j.soi.2024.100079","url":null,"abstract":"<div><h3>Background</h3><p>An ovarian mass in the setting of colorectal cancer (CRC) can be concerning due to the uncertainty of it being metastatic disease or primary ovarian neoplasm, leading to different referral and treatment options. Our objective was to determine the incidence of ovarian metastasis compared to primary ovarian pathology in women diagnosed with CRC.</p></div><div><h3>Methods</h3><p>Women aged 18 years or older, diagnosed with CRC in 2014 were included. 806 records were screened for findings of an ovarian mass until 2023. Pathology was determined via resection, biopsy, or imaging with follow-up.</p></div><div><h3>Results</h3><p>Forty women (5.0 %) had an ovarian mass; 11 at index surgery and 29 on follow-up. Median age at CRC diagnosis was 62.7 years. The incidence of Krukenberg tumour (KT) was 3.2 % accounting for 65 % of ovarian masses. Approximately 20 % presented with synchronous KTs (n = 5) and 53.8 % had synchronous peritoneal carcinomatosis (n = 14). On follow-up, KTs were found in 72.4 % of the patients (n = 21). The Overall Survival (OS) in the KT group was 7.8 % with median survival of 30.4 months. The median time to developing KTs was 20.8 months with 2-year disease-free survival of 19.2 %. Synchronous KT presentation was the only factor associated with worse OS on univariate and multivariate analysis (HR 7.23, 95 % CI 1.57–33.28, P &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>The risk of developing KT in women with CRC is 3.2 %, of which most (72.4 %) present with metachronous disease within 2 years of CRC diagnosis. Initial evaluation by a gastrointestinal tumor group is warranted.</p></div><div><h3>Synopsis</h3><p>In this multicenter study involving 806 women diagnosed with colorectal cancer, most ovarian masses that were detected during or following surgery are colorectal metastases and not primary ovarian pathology.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000884/pdfft?md5=3d9d96f443ad92eb555c16ec5e3476ca&pid=1-s2.0-S2950247024000884-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141637251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for reoperative parathyroidectomy 甲状旁腺切除术再手术策略
Pub Date : 2024-07-11 DOI: 10.1016/j.soi.2024.100078
Sanjana Balachandra, Herbert Chen

Reoperative parathyroidectomy presents unique challenges and increased risks compared to initial surgeries. A thorough preoperative assessment is crucial, incorporating history, physical exams, laboratory evaluations, imaging studies, operative notes, pathology reports analysis, and postoperative complication reviews. Ectopic parathyroid glands further complicate reoperative procedures, necessitating careful consideration in surgical planning. Radioguided parathyroidectomy offers a safe and successful option for reoperative cases, and is particularly beneficial for detecting ectopic glands.

与初次手术相比,再次手术甲状旁腺切除术面临着独特的挑战,风险也更高。全面的术前评估至关重要,包括病史、体格检查、实验室评估、影像学检查、手术记录、病理报告分析和术后并发症回顾。异位的甲状旁腺会使再次手术更加复杂,因此在制定手术计划时必须慎重考虑。放射引导甲状旁腺切除术为再手术病例提供了安全、成功的选择,尤其有利于检测异位腺体。
{"title":"Strategies for reoperative parathyroidectomy","authors":"Sanjana Balachandra,&nbsp;Herbert Chen","doi":"10.1016/j.soi.2024.100078","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100078","url":null,"abstract":"<div><p>Reoperative parathyroidectomy presents unique challenges and increased risks compared to initial surgeries. A thorough preoperative assessment is crucial, incorporating history, physical exams, laboratory evaluations, imaging studies, operative notes, pathology reports analysis, and postoperative complication reviews. Ectopic parathyroid glands further complicate reoperative procedures, necessitating careful consideration in surgical planning. Radioguided parathyroidectomy offers a safe and successful option for reoperative cases, and is particularly beneficial for detecting ectopic glands.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000872/pdfft?md5=6c57601d98cab6f5746a0382945304a7&pid=1-s2.0-S2950247024000872-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy – Impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery 腹腔内热化疗 (HIPEC) 与术后腹腔内化疗 (IP) - 对原发性卵巢癌患者接受细胞切除手术后与健康相关的生活质量的影响
Pub Date : 2024-07-04 DOI: 10.1016/j.soi.2024.100073

Purpose

To compare health-related quality of life (HRQL) in primary ovarian cancer (OC) patients with peritoneal metastases (PM) after undergoing upfront cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as part of a phase 2 trial (NCT-02124421).

Methods

Patients with stage III/IV high-grade serous OC were randomized (1:1) to either CRS/HIPEC with carboplatin followed by 6 cycles of adjuvant systemic chemotherapy (carboplatin/paclitaxel) or CRS followed by 6 cycles of combination intraperitoneal/intravenous chemotherapy (cisplatin/paclitaxel). The trial outcome index (TOI) of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire was used to assess HRQL. The FACT-O was administered at randomization and postoperatively at 6 weeks and 6, 12, and 24 months, or until disease recurrence/death. HRQL was analyzed using a linear mixed model.

Results

Sixteen patients were enrolled in each group. All (32/32) patients completed questionnaires at baseline and 53.1 % (17/32) at 24 months. Reasons for missing scores were similar between groups. Average TOI was similar between treatment arms at each time point. In both arms, mean TOI was below baseline at 6 weeks (p = 0.798) and 6 months (p = 0.821) after CRS, but recovered at 12 months (p = 0.518). No significant differences were found in FACT-O total score or FACT-O individual dimensions over time between groups.

Conclusions

No long-term HRQL impairment was observed when HIPEC was added to CRS in primary OC. Access to CRS/HIPEC as primary treatment of PM in OC should not be solely limited by concerns for patient HRQL.

Synopsis

Health-related quality of life (HRQL) was evaluated in primary ovarian cancer patients participating in a phase 2 trial comparing cytoreductive surgery (CRS)/HIPEC vs CRS + intraperitoneal (IP) chemotherapy. No differences between groups or long-term HRQL impairment were observed.

目的作为一项2期试验(NCT-02124421)的一部分,比较有腹膜转移(PM)的原发性卵巢癌(OC)患者在接受前期囊肿剥除手术并进行或不进行腹腔内热化疗(CRS/HIPEC)后的健康相关生活质量(HRQL)。方法将III/IV期高级别浆液性OC患者随机(1:1)分为两种,一种是CRS/HIPEC联合卡铂,然后进行6个周期的辅助全身化疗(卡铂/紫杉醇),另一种是CRS,然后进行6个周期的腹腔内/静脉联合化疗(顺铂/紫杉醇)。癌症治疗功能评估-卵巢(FACT-O)问卷的试验结果指数(TOI)用于评估HRQL。FACT-O 在随机化时和术后 6 周、6、12 和 24 个月或疾病复发/死亡前进行。采用线性混合模型对 HRQL 进行分析。所有患者(32/32)都在基线时填写了问卷,53.1%(17/32)的患者在 24 个月时填写了问卷。各组缺失分数的原因相似。各治疗组在每个时间点的平均TOI相似。两组患者在 CRS 后 6 周(p = 0.798)和 6 个月(p = 0.821)的平均 TOI 均低于基线,但在 12 个月时有所恢复(p = 0.518)。各组间的 FACT-O 总分或 FACT-O 单个维度随时间变化无明显差异。简要说明:对参与一项2期临床试验的原发性卵巢癌患者进行了健康相关生活质量(HRQL)评估,比较了囊肿切除手术(CRS)/HIPEC与CRS+腹腔内化疗(IP)。未观察到组间差异或长期 HRQL 损伤。
{"title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy – Impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery","authors":"","doi":"10.1016/j.soi.2024.100073","DOIUrl":"10.1016/j.soi.2024.100073","url":null,"abstract":"<div><h3>Purpose</h3><p>To compare health-related quality of life (HRQL) in primary ovarian cancer (OC) patients with peritoneal metastases (PM) after undergoing upfront cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as part of a phase 2 trial (NCT-02124421).</p></div><div><h3>Methods</h3><p>Patients with stage III/IV high-grade serous OC were randomized (1:1) to either CRS/HIPEC with carboplatin followed by 6 cycles of adjuvant systemic chemotherapy (carboplatin/paclitaxel) or CRS followed by 6 cycles of combination intraperitoneal/intravenous chemotherapy (cisplatin/paclitaxel). The trial outcome index (TOI) of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire was used to assess HRQL. The FACT-O was administered at randomization and postoperatively at 6 weeks and 6, 12, and 24 months, or until disease recurrence/death. HRQL was analyzed using a linear mixed model.</p></div><div><h3>Results</h3><p>Sixteen patients were enrolled in each group. All (32/32) patients completed questionnaires at baseline and 53.1 % (17/32) at 24 months. Reasons for missing scores were similar between groups. Average TOI was similar between treatment arms at each time point. In both arms, mean TOI was below baseline at 6 weeks (p = 0.798) and 6 months (p = 0.821) after CRS, but recovered at 12 months (p = 0.518). No significant differences were found in FACT-O total score or FACT-O individual dimensions over time between groups.</p></div><div><h3>Conclusions</h3><p>No long-term HRQL impairment was observed when HIPEC was added to CRS in primary OC. Access to CRS/HIPEC as primary treatment of PM in OC should not be solely limited by concerns for patient HRQL.</p></div><div><h3>Synopsis</h3><p>Health-related quality of life (HRQL) was evaluated in primary ovarian cancer patients participating in a phase 2 trial comparing cytoreductive surgery (CRS)/HIPEC vs CRS + intraperitoneal (IP) chemotherapy. No differences between groups or long-term HRQL impairment were observed.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000823/pdfft?md5=f53bec984c897a816cebb73fd53f1a8d&pid=1-s2.0-S2950247024000823-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141694620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving patterns of metastatic spread, treatment, and outcome for patients with oligometastatic colorectal cancer 寡转移性结直肠癌患者转移扩散、治疗和预后的演变模式
Pub Date : 2024-07-04 DOI: 10.1016/j.soi.2024.100076

Introduction

The assessment and management of oligometastatic colorectal cancer has evolved over the last two decades. We aimed to examine trends in the presentation, management and outcomes of patients presenting with liver-only disease, given recent changed standards for baseline imaging, and evolving definitions of resectability. Patients with lung-only disease can provide a contemporaneous control group.

Methods

Prospectively maintained data from the multi-site Treatment of Recurrent and Advanced Colorectal Cancer Registry were reviewed over three consecutive periods; 2009–2013, 2014–2018, and 2019–2023. Survival outcomes were determined by Kaplan-Meier method.

Results

Of 4613 patients with metastatic colorectal cancer, median age was 66 years (interquartile range 56–76), and 2356 (51 %) patients had a single metastatic site. Compared to the earlier periods, patients diagnosed in 2019–2023, were younger, had better ECOG scores and were more likely to have three or more metastatic sites. The proportion of patients with liver-only metastases decreased over the three consecutive periods, from 32.0 % (n = 462), to 27.0 % (n = 498) to 25.9 % (n = 33), p < 0.001, however the proportion of liver-only metastases patients undergoing resection increased from 41.5 to 59.3 %, p < 0.001. The incidence and resection rate of lung-only metastases was unchanged over time.

Conclusion

The increasing number of metastatic sites and reduced number of patients with liver-only metastases is potentially explained by the increased use of FDG-PET imaging at baseline. The increased proportion of patients with liver-only disease undergoing resection may be explained by advancement in surgical techniques, improvements in systemic therapies and the evolving definition of resectable disease.

Synopsis

The pattern and treatment of metastatic colorectal cancer has evolved over the last two decades. This study examines the trends in presentation management and outcomes of patients with metastatic colorectal cancer using a multi-site database.

导言在过去二十年中,对少转移性结直肠癌的评估和管理发生了变化。鉴于基线成像标准的最新变化以及可切除性定义的不断发展,我们旨在研究单纯肝脏疾病患者的表现、管理和预后趋势。方法我们回顾了2009-2013年、2014-2018年和2019-2023年三个连续时期多站点复发和晚期结直肠癌治疗登记处的前瞻性数据。结果 在4613名转移性结直肠癌患者中,中位年龄为66岁(四分位距为56-76岁),2356名患者(51%)有单一转移部位。与早期相比,2019-2023年确诊的患者更年轻,ECOG评分更高,更有可能有三个或更多转移部位。仅肝转移患者的比例在连续三个时期内有所下降,从32.0%(n = 462)到27.0%(n = 498)再到25.9%(n = 33),p <0.001,然而接受切除术的仅肝转移患者的比例从41.5%增加到59.3%,p <0.001。结论转移部位的增加和仅肝转移患者人数的减少可能是由于基线时更多地使用了 FDG-PET 成像。手术技术的进步、系统疗法的改进以及可切除疾病定义的不断发展,可能是导致接受切除术的仅肝转移患者比例增加的原因。本研究利用多站点数据库研究了转移性结直肠癌患者的治疗和预后趋势。
{"title":"Evolving patterns of metastatic spread, treatment, and outcome for patients with oligometastatic colorectal cancer","authors":"","doi":"10.1016/j.soi.2024.100076","DOIUrl":"10.1016/j.soi.2024.100076","url":null,"abstract":"<div><h3>Introduction</h3><p>The assessment and management of oligometastatic colorectal cancer has evolved over the last two decades. We aimed to examine trends in the presentation, management and outcomes of patients presenting with liver-only disease, given recent changed standards for baseline imaging, and evolving definitions of resectability. Patients with lung-only disease can provide a contemporaneous control group.</p></div><div><h3>Methods</h3><p>Prospectively maintained data from the multi-site Treatment of Recurrent and Advanced Colorectal Cancer Registry were reviewed over three consecutive periods; 2009–2013, 2014–2018, and 2019–2023. Survival outcomes were determined by Kaplan-Meier method.</p></div><div><h3>Results</h3><p>Of 4613 patients with metastatic colorectal cancer, median age was 66 years (interquartile range 56–76), and 2356 (51 %) patients had a single metastatic site. Compared to the earlier periods, patients diagnosed in 2019–2023, were younger, had better ECOG scores and were more likely to have three or more metastatic sites. The proportion of patients with liver-only metastases decreased over the three consecutive periods, from 32.0 % (n = 462), to 27.0 % (n = 498) to 25.9 % (n = 33), p &lt; 0.001, however the proportion of liver-only metastases patients undergoing resection increased from 41.5 to 59.3 %, p &lt; 0.001. The incidence and resection rate of lung-only metastases was unchanged over time.</p></div><div><h3>Conclusion</h3><p>The increasing number of metastatic sites and reduced number of patients with liver-only metastases is potentially explained by the increased use of FDG-PET imaging at baseline. The increased proportion of patients with liver-only disease undergoing resection may be explained by advancement in surgical techniques, improvements in systemic therapies and the evolving definition of resectable disease.</p></div><div><h3>Synopsis</h3><p>The pattern and treatment of metastatic colorectal cancer has evolved over the last two decades. This study examines the trends in presentation management and outcomes of patients with metastatic colorectal cancer using a multi-site database.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000859/pdfft?md5=6585052520717c8c298475369e4e20b3&pid=1-s2.0-S2950247024000859-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of sebaceous carcinoma of the breast from 2000–2023: A rare entity with high recurrence rates 2000-2023 年乳腺皮脂腺癌的系统回顾:复发率高的罕见病例
Pub Date : 2024-07-04 DOI: 10.1016/j.soi.2024.100074
Lauren N. Cohen , Colleen Flanagan , Amanda L. Kong , Chandler S. Cortina

Synopsis

Sebaceous carcinoma of the breast is a rare breast neoplasm with a small number of published cases. We report an updated systematic review of these cases to provide insight into the patient demographics, clinical presentation, and patient outcomes.

简介乳腺鳞状上皮癌是一种罕见的乳腺肿瘤,已发表的病例数量很少。我们对这些病例进行了最新的系统回顾,以深入了解患者的人口统计学特征、临床表现和预后。
{"title":"A systematic review of sebaceous carcinoma of the breast from 2000–2023: A rare entity with high recurrence rates","authors":"Lauren N. Cohen ,&nbsp;Colleen Flanagan ,&nbsp;Amanda L. Kong ,&nbsp;Chandler S. Cortina","doi":"10.1016/j.soi.2024.100074","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100074","url":null,"abstract":"<div><h3>Synopsis</h3><p>Sebaceous carcinoma of the breast is a rare breast neoplasm with a small number of published cases. We report an updated systematic review of these cases to provide insight into the patient demographics, clinical presentation, and patient outcomes.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000835/pdfft?md5=2b6d37157268a2288c9646c800b37359&pid=1-s2.0-S2950247024000835-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of irreversible electroporation on survival among patients with borderline resectable/locally advanced pancreatic cancer: A single center experience 不可逆电穿孔术对边缘可切除/局部晚期胰腺癌患者生存期的影响:单中心经验
Pub Date : 2024-07-04 DOI: 10.1016/j.soi.2024.100075
Mohammed O. Suraju , Yutao Su , Jeremy Chang , Aditi Katwala , Apoorve Nayyar , Darren M. Gordon , Scott K. Sherman , Hisakazu Hoshi , James R. Howe , Carlos H.F. Chan

Background

The use of Irreversible Electroporation (IRE) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) is increasing. However, its potential impact on survival has been debated. We hypothesized that addition of IRE to the conventional multimodal therapy would be associated with improved overall survival (OS) in BR/LA PDAC patients.

Methods

Among patients received neoadjuvant chemotherapy, we identified PDAC patients with BR/LA disease who underwent resection alone, resection+IRE, IRE alone, and no resection but would have been eligible for IRE. Kaplan-Meier method with Peto-Peto modified log-rank test and Cox proportional hazard were used in survival analyses.

Results

102 patients were included in the cohort – 40 resection-only (18 % LA), 13 resection+IRE (46 % LA), 14 IRE-only (93 % LA), and 35 unresected (77 % LA). Median age was 65. IRE patients had a median follow-up of 22 months [95 %CI:14–28], while for non-IRE patients it was 17 months [95 %CI:12–26]. Median age and proportion without comorbidities did not significantly differ across groups. Median OS was 30 months [95 %CI:30-NR] among patients who underwent resection+IRE, 27 months [95 %CI:23–48] for resection-only, 28 months [95 %CI:16-NR] for IRE-only, and 14 months [95 %CI:10–20] for unresected patients. In multivariable analyses, resection (HR:0.26 [95 %CI:0.13–0.54], P < 0.001), neoadjuvant chemoradiation (HR:0.50 [95 %CI:0.28–0.88], P = 0.017), and IRE (HR:0.49 [95 %CI:0.26–0.94], P = 0.03) were independently associated with decreased risk of mortality.

Conclusions

IRE may enhance survival in BR/LA PDAC patients who receive conventional multimodal therapy. Prospective studies are needed to confirm the potential benefits of IRE as an adjunct during pancreatic resection after multimodal neoadjuvant therapy for BR/LA PDAC.

Synopsis

Irreversible electroporation can be a valuable adjunct to the current multimodal therapy for treating borderline resectable and locally advanced pancreatic cancer.

背景不可逆电穿孔术(IRE)在边缘可切除(BR)和局部晚期(LA)胰腺导管腺癌(PDAC)中的应用日益增多。然而,其对存活率的潜在影响一直存在争议。在接受新辅助化疗的患者中,我们发现了患有 BR/LA 疾病的 PDAC 患者,他们分别接受了单纯切除术、切除术+IRE、单纯 IRE 以及未接受切除术但符合 IRE 治疗条件。结果102例患者被纳入队列--40例单纯切除(18% LA)、13例切除+IRE(46% LA)、14例单纯IRE(93% LA)和35例未切除(77% LA)。中位年龄为 65 岁。IRE患者的中位随访时间为22个月[95%CI:14-28],而非IRE患者的中位随访时间为17个月[95%CI:12-26]。各组患者的中位年龄和无合并症的比例无明显差异。接受切除+IRE的患者中位OS为30个月[95 %CI:30-NR],仅接受切除的患者为27个月[95 %CI:23-48],仅接受IRE的患者为28个月[95 %CI:16-NR],未接受切除的患者为14个月[95 %CI:10-20]。在多变量分析中,切除(HR:0.26 [95 %CI:0.13-0.54], P < 0.001)、新辅助化疗(HR:0.50 [95 %CI:0.28-0.88], P = 0.017)和IRE(HR:0.49 [95 %CI:0.26-0.结论IRE可提高接受常规多模式治疗的BR/LA PDAC患者的生存率。需要进行前瞻性研究,以证实 IRE 作为 BR/LA PDAC 多模式新辅助治疗后胰腺切除术的辅助手段可能带来的益处。
{"title":"Impact of irreversible electroporation on survival among patients with borderline resectable/locally advanced pancreatic cancer: A single center experience","authors":"Mohammed O. Suraju ,&nbsp;Yutao Su ,&nbsp;Jeremy Chang ,&nbsp;Aditi Katwala ,&nbsp;Apoorve Nayyar ,&nbsp;Darren M. Gordon ,&nbsp;Scott K. Sherman ,&nbsp;Hisakazu Hoshi ,&nbsp;James R. Howe ,&nbsp;Carlos H.F. Chan","doi":"10.1016/j.soi.2024.100075","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100075","url":null,"abstract":"<div><h3>Background</h3><p>The use of Irreversible Electroporation (IRE) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) is increasing. However, its potential impact on survival has been debated. We hypothesized that addition of IRE to the conventional multimodal therapy would be associated with improved overall survival (OS) in BR/LA PDAC patients.</p></div><div><h3>Methods</h3><p>Among patients received neoadjuvant chemotherapy, we identified PDAC patients with BR/LA disease who underwent resection alone, resection+IRE, IRE alone, and no resection but would have been eligible for IRE. Kaplan-Meier method with Peto-Peto modified log-rank test and Cox proportional hazard were used in survival analyses.</p></div><div><h3>Results</h3><p>102 patients were included in the cohort – 40 resection-only (18 % LA), 13 resection+IRE (46 % LA), 14 IRE-only (93 % LA), and 35 unresected (77 % LA). Median age was 65. IRE patients had a median follow-up of 22 months [95 %CI:14–28], while for non-IRE patients it was 17 months [95 %CI:12–26]. Median age and proportion without comorbidities did not significantly differ across groups. Median OS was 30 months [95 %CI:30-NR] among patients who underwent resection+IRE, 27 months [95 %CI:23–48] for resection-only, 28 months [95 %CI:16-NR] for IRE-only, and 14 months [95 %CI:10–20] for unresected patients. In multivariable analyses, resection (HR:0.26 [95 %CI:0.13–0.54], <em>P</em> &lt; 0.001), neoadjuvant chemoradiation (HR:0.50 [95 %CI:0.28–0.88], <em>P</em> = 0.017), and IRE (HR:0.49 [95 %CI:0.26–0.94], <em>P</em> = 0.03) were independently associated with decreased risk of mortality.</p></div><div><h3>Conclusions</h3><p>IRE may enhance survival in BR/LA PDAC patients who receive conventional multimodal therapy. Prospective studies are needed to confirm the potential benefits of IRE as an adjunct during pancreatic resection after multimodal neoadjuvant therapy for BR/LA PDAC.</p></div><div><h3>Synopsis</h3><p>Irreversible electroporation can be a valuable adjunct to the current multimodal therapy for treating borderline resectable and locally advanced pancreatic cancer.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000847/pdfft?md5=579a9caf5cd707c0b3ca943b58830539&pid=1-s2.0-S2950247024000847-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective multi-institutional trial examining the feasibility, accuracy and learning curve of fluorescence imaging for sentinel node localization in melanoma 一项前瞻性多机构试验,研究用于黑色素瘤前哨节点定位的荧光成像技术的可行性、准确性和学习曲线
Pub Date : 2024-06-27 DOI: 10.1016/j.soi.2024.100071
Colette R. Pameijer , Rogerio I. Neves , James R. Nitzkorski , Michael C. Lowe

Background

Sentinel node biopsy is a standard component of staging for patients with melanoma. Lymphoscintigraphy with technetium99 (99mTc) is highly reliable but not patient centered, requiring a separate visit to radiology and often a painful injection. We assessed intra-operative real-time fluorescence lymphangiography as an alternative to 99mTc for sentinel node localization in patients with extremity melanoma.

Methods

A multi-center single arm prospective trial was conducted for patients with extremity melanoma. All subjects had lymphoscintigraphy with 99mTc prior to surgery and a dermal injection of indocyanine green in the operating room. The surgeon was blinded to the lymphoscintigraphy results and used real-time fluorescence imaging to localize the sentinel nodes. Success rate and operative times were recorded.

Results

Four surgeons enrolled 35 subjects with melanoma of the upper or lower extremity, excluding hands and feet, who met criteria for sentinel node biopsy based on NCCN guidelines. Each surgeon enrolled at least 8 subjects. The overall success rate for the first sentinel node was 83 % (29/35). The success rate varied between the axilla and groin, and between first, second and third sentinel nodes. The average time to identify the first sentinel node was 14 min, with no consistent improvement over time. There were no complications related to the ICG.

Conclusions

The success rate of sentinel node localization with indocyanine green and fluorescence imaging is high, but not high enough to use this method alone. ICG can safely replace blue dye. The learning curve for this technique is likely more than 8 patients.

Synopsis

ICG and fluorescence imaging may aid in sentinel node localization but should not replace lymphoscintigraphy with 99mTc. ICG with fluorescence imaging can safely replace blue dye. The learning curve for this technique is at least 8 patients.

背景前哨节点活检是黑色素瘤患者分期的标准组成部分。使用锝99(99mTc)进行淋巴管造影的可靠性很高,但不是以病人为中心,需要单独到放射科就诊,而且注射时往往很痛苦。我们对四肢黑色素瘤患者术中实时荧光淋巴管造影替代 99mTc 进行前哨节点定位进行了评估。所有受试者都在手术前接受了99m锝淋巴管造影,并在手术室进行了吲哚菁绿的皮肤注射。外科医生对淋巴管造影结果是盲法,并使用实时荧光成像来定位前哨结节。结果四位外科医生共招募了35名上肢或下肢(不包括手和脚)黑色素瘤患者,他们都符合根据NCCN指南进行前哨节点活检的标准。每位外科医生至少招募了 8 名受试者。第一个前哨节点的总体成功率为 83%(29/35)。腋窝和腹股沟的成功率不同,第一个、第二个和第三个前哨结节的成功率也不同。确定第一个前哨结节的平均时间为 14 分钟,随着时间的推移没有持续性的改善。结论使用吲哚菁绿和荧光成像进行前哨节点定位的成功率很高,但还不足以单独使用这种方法。ICG 可以安全地取代蓝色染料。吲哚菁绿和荧光成像可帮助前哨节点定位,但不应取代 99mTc 淋巴闪烁成像。ICG荧光成像可以安全地取代蓝色染料。这项技术的学习曲线至少需要 8 名患者。
{"title":"A prospective multi-institutional trial examining the feasibility, accuracy and learning curve of fluorescence imaging for sentinel node localization in melanoma","authors":"Colette R. Pameijer ,&nbsp;Rogerio I. Neves ,&nbsp;James R. Nitzkorski ,&nbsp;Michael C. Lowe","doi":"10.1016/j.soi.2024.100071","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100071","url":null,"abstract":"<div><h3>Background</h3><p>Sentinel node biopsy is a standard component of staging for patients with melanoma. Lymphoscintigraphy with technetium99 (<sup>99m</sup>Tc) is highly reliable but not patient centered, requiring a separate visit to radiology and often a painful injection. We assessed intra-operative real-time fluorescence lymphangiography as an alternative to <sup>99m</sup>Tc for sentinel node localization in patients with extremity melanoma.</p></div><div><h3>Methods</h3><p>A multi-center single arm prospective trial was conducted for patients with extremity melanoma. All subjects had lymphoscintigraphy with <sup>99m</sup>Tc prior to surgery and a dermal injection of indocyanine green in the operating room. The surgeon was blinded to the lymphoscintigraphy results and used real-time fluorescence imaging to localize the sentinel nodes. Success rate and operative times were recorded.</p></div><div><h3>Results</h3><p>Four surgeons enrolled 35 subjects with melanoma of the upper or lower extremity, excluding hands and feet, who met criteria for sentinel node biopsy based on NCCN guidelines. Each surgeon enrolled at least 8 subjects. The overall success rate for the first sentinel node was 83 % (29/35). The success rate varied between the axilla and groin, and between first, second and third sentinel nodes. The average time to identify the first sentinel node was 14 min, with no consistent improvement over time. There were no complications related to the ICG.</p></div><div><h3>Conclusions</h3><p>The success rate of sentinel node localization with indocyanine green and fluorescence imaging is high, but not high enough to use this method alone. ICG can safely replace blue dye. The learning curve for this technique is likely more than 8 patients.</p></div><div><h3>Synopsis</h3><p>ICG and fluorescence imaging may aid in sentinel node localization but should not replace lymphoscintigraphy with <sup>99m</sup>Tc. ICG with fluorescence imaging can safely replace blue dye. The learning curve for this technique is at least 8 patients.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295024702400080X/pdfft?md5=683c2bca3c4ec84b4155dd046af1108d&pid=1-s2.0-S295024702400080X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141483505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors of a positive resection margin in locoregional appendix cancer and its impact on survival: The national cancer database analysis 局部阑尾癌切除边缘阳性的风险因素及其对生存的影响:国家癌症数据库分析
Pub Date : 2024-06-26 DOI: 10.1016/j.soi.2024.100072
Ekaterina Baron, Chih Ching Wu, Andrei Nikiforchin, Raquel Abengozar Mingorance, Stephanie C. Carr, Jessica A. Wernberg, Rohit Sharma

Introduction

The impact of a positive resection margin (RM+) in appendiceal cancer (AC) remains unclear, with small studies suggesting it does not worsen survival in low-grade subtypes. We aimed to evaluate RM+ rates, its risk factors, and survival outcomes across different AC histologies.

Methods

We conducted a multicenter retrospective cohort study using the National Cancer Database (2004–2019) and including stage I-III AC cases. Surgical and survival outcomes were compared between RM+ and RM- groups, with logistic regression analyzing the association of RM+ and its predictors. Subgroup analysis was performed for low/high tumor grade (LG/HG), mucinous/non-mucinous pathology (MAC/NMAC), and signet ring cell carcinoma (SRC).

Results

Among 6800 patients identified, 737 (10.8 %) had RM+, while 6063 (89.2 %) had RM-. RM+ rates varied across AC histologies: 10.9 % in LG-MAC, 17.0 % in HG-MAC, 7.8 % in LG-NMAC, 13.9 % in HG-NMAC, and 17.9 % in SRC. RM+ correlated with significantly worse survival in LG-MAC (HR 1.67), HG-MAC (HR 1.83), LG-NMAC (HR 2.04), and SRC (HR 2.37) but not in HG-NMAC after adjusting to other factors. Predictors of RM+ included pT stage, preoperative chemotherapy in LG tumors and pT stage and positive lymph nodes in HG tumors whereas more extensive resection was associated with RM- in both LG and HG.

Conclusion

RM+ worsens survival in most AC subtypes, highlighting the importance of achieving negative margins. Extensive resection, like right hemicolectomy, can improve RM- rate, but factors such as pT stage, lymph node status, and preoperative chemotherapy also affect RM+. Surgeons should prioritize achieving RM- in all AC histologies.

导言切除边缘阳性(RM+)对阑尾癌(AC)的影响仍不明确,一些小型研究表明它不会恶化低级别亚型的生存率。我们利用全国癌症数据库(2004-2019 年)开展了一项多中心回顾性队列研究,其中包括 I-III 期阑尾癌病例。比较了RM+组和RM-组的手术和生存结果,并通过逻辑回归分析了RM+与其预测因素的关联。对低/高肿瘤分级(LG/HG)、粘液性/非粘液性病理(MAC/NMAC)和标志环细胞癌(SRC)进行了亚组分析。结果在6800例已确定的患者中,737例(10.8%)为RM+,6063例(89.2%)为RM-。不同组织学的 AC RM+ 率各不相同:LG-MAC为10.9%,HG-MAC为17.0%,LG-NMAC为7.8%,HG-NMAC为13.9%,SRC为17.9%。在 LG-MAC(HR 1.67)、HG-MAC(HR 1.83)、LG-NMAC(HR 2.04)和 SRC(HR 2.37)中,RM+ 与明显较差的存活率相关,但在调整其他因素后,在 HG-NMAC 中则不相关。RM+的预测因素包括LG肿瘤的pT分期和术前化疗,以及HG肿瘤的pT分期和淋巴结阳性,而在LG和HG中,更广泛的切除与RM-有关。广泛切除(如右半结肠切除术)可提高RM-率,但pT分期、淋巴结状态和术前化疗等因素也会影响RM+。外科医生应优先考虑在所有 AC 组织学中实现 RM-。
{"title":"Risk factors of a positive resection margin in locoregional appendix cancer and its impact on survival: The national cancer database analysis","authors":"Ekaterina Baron,&nbsp;Chih Ching Wu,&nbsp;Andrei Nikiforchin,&nbsp;Raquel Abengozar Mingorance,&nbsp;Stephanie C. Carr,&nbsp;Jessica A. Wernberg,&nbsp;Rohit Sharma","doi":"10.1016/j.soi.2024.100072","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100072","url":null,"abstract":"<div><h3>Introduction</h3><p>The impact of a positive resection margin (RM+) in appendiceal cancer (AC) remains unclear, with small studies suggesting it does not worsen survival in low-grade subtypes. We aimed to evaluate RM+ rates, its risk factors, and survival outcomes across different AC histologies.</p></div><div><h3>Methods</h3><p>We conducted a multicenter retrospective cohort study using the National Cancer Database (2004–2019) and including stage I-III AC cases. Surgical and survival outcomes were compared between RM+ and RM- groups, with logistic regression analyzing the association of RM+ and its predictors. Subgroup analysis was performed for low/high tumor grade (LG/HG), mucinous/non-mucinous pathology (MAC/NMAC), and signet ring cell carcinoma (SRC).</p></div><div><h3>Results</h3><p>Among 6800 patients identified, 737 (10.8 %) had RM+, while 6063 (89.2 %) had RM-. RM+ rates varied across AC histologies: 10.9 % in LG-MAC, 17.0 % in HG-MAC, 7.8 % in LG-NMAC, 13.9 % in HG-NMAC, and 17.9 % in SRC. RM+ correlated with significantly worse survival in LG-MAC (HR 1.67), HG-MAC (HR 1.83), LG-NMAC (HR 2.04), and SRC (HR 2.37) but not in HG-NMAC after adjusting to other factors. Predictors of RM+ included pT stage, preoperative chemotherapy in LG tumors and pT stage and positive lymph nodes in HG tumors whereas more extensive resection was associated with RM- in both LG and HG.</p></div><div><h3>Conclusion</h3><p>RM+ worsens survival in most AC subtypes, highlighting the importance of achieving negative margins. Extensive resection, like right hemicolectomy, can improve RM- rate, but factors such as pT stage, lymph node status, and preoperative chemotherapy also affect RM+. Surgeons should prioritize achieving RM- in all AC histologies.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000811/pdfft?md5=bea5968875967fb0b29097f4858ba440&pid=1-s2.0-S2950247024000811-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased rate of upstaging of plantar melanomas may warrant more radical treatment: Study at a single NCI-designated Cancer Center 足底黑色素瘤的上行分期率增加,可能需要更彻底的治疗:美国国家癌症研究所(NCI)指定的一家癌症中心的研究
Pub Date : 2024-06-24 DOI: 10.1016/j.soi.2024.100070
Michelle Jeffery , Vasileios Tsagkalidis , Brennan Cook , Vadim Koshenkov , Adam C. Berger

Background

Acral lentiginous melanoma holds the worst prognosis of all cutaneous melanomas. We aim to further detail the incidence of upstaging in plantar melanoma (PM) as well as identify factors associated with upstaging.

Methods

A retrospective analysis of medical records was performed of patients who underwent surgical intervention for non-metastatic primary PM at a single NCI-designated Comprehensive Cancer Center (January 2011-August 2023). The primary outcome was rate of upstaging, defined as an increase in the T-stage on final surgical pathology compared to biopsy. Clinical and pathologic staging were determined by the AJCC 8th edition. Statistical analysis included Pearson’s Chi-squared test, Fisher’s exact test, Wilcoxon rank sum test, and Kruskal-Wallis rank sum test.

Results

Forty-nine patients were identified, with an average age of 65 years (51 % male). Majority self-identified as Caucasian (55 %). Initial biopsy techniques were shave (49 %), punch (34 %) and excisional (17 %). Twenty-four patients (50 %) demonstrated upstaging. Seventy-seven percent (n = 10) of patients with clinical Tis were upstaged. Eight patients required reoperation due to upstaging, with 6 having melanoma in situ on biopsy. On multivariable logistic regression, patients with clinical Tis-T1 were more likely to be upstaged compared to T2-T3 (OR 8.75, p < 0.041). Type of biopsy, lesion size < 15 mm and positive deep margins on biopsy were not associated with risk of upstaging.

Conclusions

Our findings suggest a high incidence of upstaging of PM with no identifiable factors associated with upstaging. Patients with clinical Tis or T1 PM should undergo resection with wider margins and be strongly considered for sentinel lymph node biopsy at time of index operation.

Synopsis

In this large cohort of patients with non-metastatic primary plantar melanoma, half of the cohort was upstaged following resection. The risk was higher in patients diagnosed with Tis or T1 on biopsy compared to T2-T3. Biopsy type, lesion size < 15 mm and positive deep biopsy margins were not associated with upstaging. More radical treatment of plantar melanomas may be warranted.

背景鳞状黑色素瘤是所有皮肤黑色素瘤中预后最差的一种。我们旨在进一步详细了解足底黑色素瘤(PM)的上行分期发生率,并确定与上行分期相关的因素。方法我们对一家美国国立癌症研究院(NCI)指定的综合癌症中心(2011 年 1 月至 2023 年 8 月)中因非转移性原发性足底黑色素瘤接受手术治疗的患者的病历进行了回顾性分析。主要研究结果是上行分期率,即最终手术病理结果与活检结果相比T分期增加。临床和病理分期由 AJCC 第 8 版确定。统计分析包括皮尔逊卡方检验、费雪精确检验、Wilcoxon 秩和检验和 Kruskal-Wallis 秩和检验。大多数患者自称是白种人(55%)。最初的活检技术为刮片(49%)、打孔(34%)和切除(17%)。二十四名患者(50%)表现为上分期。在临床 Tis 患者中,77%(n = 10)的患者进行了向上分期。八名患者因上行分期而需要再次手术,其中六名患者的活检结果为原位黑色素瘤。多变量逻辑回归结果显示,与T2-T3相比,临床Tis-T1患者更有可能向上分期(OR 8.75,p <0.041)。活检类型、病变大小< 15 mm和活检深部边缘阳性与上行分期风险无关。临床表现为Tis或T1 PM的患者应接受边缘更宽的切除术,并在进行索引手术时积极考虑前哨淋巴结活检。与T2-T3相比,活检诊断为Tis或T1的患者风险更高。活检类型、病变大小< 15毫米和深部活检边缘阳性与分期上升无关。可能需要对足底黑色素瘤进行更彻底的治疗。
{"title":"Increased rate of upstaging of plantar melanomas may warrant more radical treatment: Study at a single NCI-designated Cancer Center","authors":"Michelle Jeffery ,&nbsp;Vasileios Tsagkalidis ,&nbsp;Brennan Cook ,&nbsp;Vadim Koshenkov ,&nbsp;Adam C. Berger","doi":"10.1016/j.soi.2024.100070","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100070","url":null,"abstract":"<div><h3>Background</h3><p>Acral lentiginous melanoma holds the worst prognosis of all cutaneous melanomas. We aim to further detail the incidence of upstaging in plantar melanoma (PM) as well as identify factors associated with upstaging.</p></div><div><h3>Methods</h3><p>A retrospective analysis of medical records was performed of patients who underwent surgical intervention for non-metastatic primary PM at a single NCI-designated Comprehensive Cancer Center (January 2011-August 2023). The primary outcome was rate of upstaging, defined as an increase in the T-stage on final surgical pathology compared to biopsy. Clinical and pathologic staging were determined by the AJCC 8th edition. Statistical analysis included Pearson’s Chi-squared test, Fisher’s exact test, Wilcoxon rank sum test, and Kruskal-Wallis rank sum test.</p></div><div><h3>Results</h3><p>Forty-nine patients were identified, with an average age of 65 years (51 % male). Majority self-identified as Caucasian (55 %). Initial biopsy techniques were shave (49 %), punch (34 %) and excisional (17 %). Twenty-four patients (50 %) demonstrated upstaging. Seventy-seven percent (n = 10) of patients with clinical Tis were upstaged. Eight patients required reoperation due to upstaging, with 6 having melanoma in situ on biopsy. On multivariable logistic regression, patients with clinical Tis-T1 were more likely to be upstaged compared to T2-T3 (OR 8.75, p &lt; 0.041). Type of biopsy, lesion size &lt; 15 mm and positive deep margins on biopsy were not associated with risk of upstaging.</p></div><div><h3>Conclusions</h3><p>Our findings suggest a high incidence of upstaging of PM with no identifiable factors associated with upstaging. Patients with clinical Tis or T1 PM should undergo resection with wider margins and be strongly considered for sentinel lymph node biopsy at time of index operation.</p></div><div><h3>Synopsis</h3><p>In this large cohort of patients with non-metastatic primary plantar melanoma, half of the cohort was upstaged following resection. The risk was higher in patients diagnosed with Tis or T1 on biopsy compared to T2-T3. Biopsy type, lesion size &lt; 15 mm and positive deep biopsy margins were not associated with upstaging. More radical treatment of plantar melanomas may be warranted.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000793/pdfft?md5=52147f236ba1e9580635be5863c0208e&pid=1-s2.0-S2950247024000793-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of surgical margin on prognosis after hepatectomy for colorectal cancer liver metastases with RAS mutations RAS突变的结直肠癌肝转移灶肝切除术后手术切缘与预后的关系
Pub Date : 2024-06-24 DOI: 10.1016/j.soi.2024.100069
Takuya Tajiri, Kosuke Mima, Hiromitsu Hayashi , Yuji Miyamoto, Yuki Adachi, Takashi Ofuchi, Kosuke Kanemitsu, Toru Takematsu, Rumi Itoyama., Yuki Kitano, Shigeki Nakagawa, Hirohisa Okabe, Katsunori Imai, Hideo Baba

Background

Although outcomes of treatment for colorectal cancer liver metastases (CRLM) have improved with multidisciplinary treatment, recurrence rates after resection of liver metastases are still high. Although surgical margin (SM) is considered irrelevant in the case of R0 resection, its effectiveness is still unclear. In this study, we investigated the prognostic association of SM in CRLM according to RAS status.

Methods

Of 220 patients who had undergone initial hepatic resection for CRLM at our hospital between January 2000 and February 2020, finally, 164 remained in the study cohort. SMs (mms) were measured by macroscopic and microscopic examinations. Associations between SM, presence or absence of RAS mutations, and prognosis were analyzed using multivariate analysis with the Cox proportional hazards model.

Results

Of the 164 patients, 68 (41 %) had RAS mutations. The RAS mutation group had significantly poorer disease-free survival (DFS) (P < 0.001) and over-all survival (OS) (P < 0.001). In the RAS wild group, SM status was not significantly associated with OS or DFS, whereas in the RAS mutation group, SM< 2 mm was significantly associated with worse DFS (P = 0.014). Multivariate analysis showed that SM< 2 mm was an independent predictor of poor DFS in the RAS mutation group (HR 21.3, 95 % CI: 2.25–201.3, P = 0.008).

Conclusions

RAS mutation status is an independent predictor of poor prognosis after hepatectomy for CRLM. Especially in patients with RAS mutations, SM < 2 mm is associated with significantly worse post-hepatectomy DFS, suggesting achieving a wide SM (≥2 mm) is indicated in patients with RAS mutations

Synopsis

RAS mutation is an independent predictor of poor prognosis after hepatectomy for CRLM. Especially in patients with RAS mutations, SM < 2 mm is associated with significantly worse post-hepatectomy DFS, suggesting achieving a wide SM (≥2 mm) is indicated.

背景虽然结直肠癌肝转移(CRLM)的治疗效果在多学科治疗后有所改善,但肝转移灶切除后的复发率仍然很高。虽然手术切缘(SM)被认为与 R0 切除无关,但其有效性仍不明确。在本研究中,我们根据 RAS 状态研究了 SM 与 CRLM 预后的相关性。方法在 2000 年 1 月至 2020 年 2 月期间,我院对 220 例 CRLM 患者进行了初次肝切除术,最终有 164 例患者留在了研究队列中。通过宏观和微观检查测量了SMs(mms)。采用Cox比例危险度模型进行多变量分析,分析SM、是否存在RAS突变与预后之间的关系。RAS突变组的无病生存期(DFS)(P <0.001)和总生存期(OS)(P <0.001)明显较差。在RAS野生组中,SM状态与OS或DFS无明显相关性,而在RAS突变组中,SM< 2 mm与较差的DFS明显相关(P = 0.014)。多变量分析显示,SM< 2 mm 是 RAS 突变组 DFS 差的独立预测因子(HR 21.3,95 % CI:2.25-201.3,P = 0.008)。特别是在 RAS 突变的患者中,SM < 2 mm 与肝切除术后 DFS 明显较差相关,提示 RAS 突变患者应达到宽 SM(≥2 mm)。特别是在RAS突变的患者中,SM < 2 mm与肝切除术后DFS明显较差有关,这表明应实现宽SM(≥2 mm)。
{"title":"Association of surgical margin on prognosis after hepatectomy for colorectal cancer liver metastases with RAS mutations","authors":"Takuya Tajiri,&nbsp;Kosuke Mima,&nbsp;Hiromitsu Hayashi ,&nbsp;Yuji Miyamoto,&nbsp;Yuki Adachi,&nbsp;Takashi Ofuchi,&nbsp;Kosuke Kanemitsu,&nbsp;Toru Takematsu,&nbsp;Rumi Itoyama.,&nbsp;Yuki Kitano,&nbsp;Shigeki Nakagawa,&nbsp;Hirohisa Okabe,&nbsp;Katsunori Imai,&nbsp;Hideo Baba","doi":"10.1016/j.soi.2024.100069","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100069","url":null,"abstract":"<div><h3>Background</h3><p>Although outcomes of treatment for colorectal cancer liver metastases (CRLM) have improved with multidisciplinary treatment, recurrence rates after resection of liver metastases are still high. Although surgical margin (SM) is considered irrelevant in the case of R0 resection, its effectiveness is still unclear. In this study, we investigated the prognostic association of SM in CRLM according to RAS status.</p></div><div><h3>Methods</h3><p>Of 220 patients who had undergone initial hepatic resection for CRLM at our hospital between January 2000 and February 2020, finally, 164 remained in the study cohort. SMs (mms) were measured by macroscopic and microscopic examinations. Associations between SM, presence or absence of RAS mutations, and prognosis were analyzed using multivariate analysis with the Cox proportional hazards model.</p></div><div><h3>Results</h3><p>Of the 164 patients, 68 (41 %) had RAS mutations. The RAS mutation group had significantly poorer disease-free survival (DFS) (P &lt; 0.001) and over-all survival (OS) (P &lt; 0.001). In the RAS wild group, SM status was not significantly associated with OS or DFS, whereas in the RAS mutation group, SM&lt; 2 mm was significantly associated with worse DFS (P = 0.014). Multivariate analysis showed that SM&lt; 2 mm was an independent predictor of poor DFS in the RAS mutation group (HR 21.3, 95 % CI: 2.25–201.3, P = 0.008).</p></div><div><h3>Conclusions</h3><p>RAS mutation status is an independent predictor of poor prognosis after hepatectomy for CRLM. Especially in patients with RAS mutations, SM &lt; 2 mm is associated with significantly worse post-hepatectomy DFS, suggesting achieving a wide SM (≥2 mm) is indicated in patients with RAS mutations</p></div><div><h3>Synopsis</h3><p>RAS mutation is an independent predictor of poor prognosis after hepatectomy for CRLM. Especially in patients with RAS mutations, SM &lt; 2 mm is associated with significantly worse post-hepatectomy DFS, suggesting achieving a wide SM (≥2 mm) is indicated.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000781/pdfft?md5=edc6796eeeded4f9d4a45fced5555942&pid=1-s2.0-S2950247024000781-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Surgical Oncology Insight
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1